Stefan N
Abteilung für Innere Medizin IV, Bereiche Endokrinologie, Diabetologie, Angiologie, Nephrologie und Klinische Chemie, Universitätsklinikum Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Deutschland.
Abteilung für Pathophysiologie des Prädiabetes, Institut für Diabetesforschung und Metabolische Erkrankungen (IDM), Helmholtz Zentrum München, Universität Tübingen, Tübingen, Deutschland.
Internist (Berl). 2019 Feb;60(2):128-132. doi: 10.1007/s00108-018-0550-y.
During the past 10 years nonalcoholic fatty liver disease (NAFLD) has moved more and more into the focus of attention of clinical research. The term NAFLD comprises the simple nonalcoholic steatosis or fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). As the incidence of NAFLD has dramatically increased, it is expected that during the coming years NASH in particular will become the main reason for liver transplantation in industrialized countries. In addition, it has become evident that scirrhotic liver fibrosis can develop directly from NAFL without going through the stage of NASH. Finally, there is accumulating evidence that both NAFL and NASH are strongly associated with an increased risk of type 2 diabetes and cardiovascular diseases and on the other hand that NAFL and NASH are complications of diabetes. This article addresses the current knowledge about the prevalence, diagnosis, risk prediction and treatment of NAFLD.
在过去10年里，非酒精性脂肪性肝病（NAFLD）越来越成为临床研究关注的焦点。NAFLD这一术语包括单纯性非酒精性脂肪变性或脂肪肝（NAFL）以及非酒精性脂肪性肝炎（NASH）。由于NAFLD的发病率急剧上升，预计在未来几年，尤其是NASH将成为工业化国家肝移植的主要原因。此外，已经很明显，肝硬化肝纤维化可以直接从NAFL发展而来，而无需经历NASH阶段。最后，越来越多的证据表明，NAFL和NASH都与2型糖尿病和心血管疾病风险增加密切相关，另一方面，NAFL和NASH也是糖尿病的并发症。本文阐述了关于NAFLD的患病率、诊断、风险预测和治疗的当前知识。
